Drugs / Norgestimate/ethinyl estradiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02533427 | Oct 2015 → Mar 2016 | hepatitis C virus infection | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norgestimate/ethinyl estradiol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02533427 ↗ |
| Route | Oral | “Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert” NCT02533427 ↗ |